Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Editas Medicine (EDIT) Non-cash Items: 2015-2023

Historic Non-cash Items for Editas Medicine (EDIT) over the last 7 years, with Jun 2023 value amounting to $2.6 million.

  • Editas Medicine's Non-cash Items fell 99.76% to $2.6 million in Q2 2023 from the same period last year, while for Jun 2023 it was $2.6 million, marking a year-over-year decrease of 99.76%. This contributed to the annual value of $401.5 million for FY2022, which is 92.05% down from last year.
  • Editas Medicine's Non-cash Items amounted to $2.6 million in Q2 2023, which was up 17.60% from $2.2 million recorded in Q1 2023.
  • In the past 5 years, Editas Medicine's Non-cash Items registered a high of $5.1 billion during Q4 2021, and its lowest value of $1.3 million during Q2 2021.
  • In the last 3 years, Editas Medicine's Non-cash Items had a median value of $2.1 million in 2022 and averaged $1.0 billion.
  • Over the last 5 years, Editas Medicine's Non-cash Items had its largest YoY gain of 262,951.33% in 2022, and its largest YoY loss of 99.96% in 2022.
  • Quarterly analysis of 5 years shows Editas Medicine's Non-cash Items stood at $26.1 million in 2019, then skyrocketed by 543.28% to $167.6 million in 2020, then surged by 2,913.88% to $5.1 billion in 2021, then crashed by 99.96% to $2.0 million in 2022, then tumbled by 99.76% to $2.6 million in 2023.
  • Its Non-cash Items stands at $2.6 million for Q2 2023, versus $2.2 million for Q1 2023 and $2.0 million for Q4 2022.